Skip to main content
Translational Immunology and Immunotherapy Retreat 2021 logo
 

5th Annual Translational Cancer Immunotherapy Retreat

Tuesday, October 24 2023
Memphis Brooks Museum of Art

 
 

The Translational Cancer Immunotherapy Retreat is an interactive, one-day event, designated to foster collaboration and share ongoing cancer immunotherapy related research. Invited speakers include St. Jude trainees who will share their cancer immunotherapy focused projects, St. Jude faculty who will present updates on state of cancer immunotherapy and ongoing clinical trials at St. Jude as well as a keynote presenter Jian Xu, PhD, Department of Pathology. Key challenges and future directions of the program will be discussed to generate engagement and collaboration.

Hosts

Organized by the Department of Bone Marrow Transplantation and Cellular Therapy and the Department of Immunology.

 

Agenda

 

Session I

Chair: Elizabeth Wickman, PhD

 
Time Topic Speaker(s)
8:00-8:30 am Breakfast
8:30-8:45 am Welcome and Update on Cell Therapy at St. Jude Stephen Gottschalk, MD
8:45-9:00 am Single-cell functional genomics to map antitumor immunity Peipei Zhou, PhD (Chi Lab)
9:00-9:15 am GPR65 inactivation in tumor cells drives antigen-independent CAR-T resistance via VEGF-mediated macrophage remodeling Jayadev Mavuluri, PhD (Geiger Lab)
9:15-9:30 am Regnase-1 deletion improves B7-H3-CAR T cell therapy for solid tumors Adeleye Adeshakin, PhD (Gottschalk Lab)
9:30-9:45 am Investigating the impact of epigenetic modification on the anti-tumor efficacy of CAR T cells against Group 3 medulloblastomas Meghan Dukes, PhD (Krenciute Lab)
9:45-10:00 am Clinical Update Chris DeRenzo, MD, MBA
10:00-10:15 am Break and poster setup
 

Session II: Keynote Speaker

Chair: Hongbo Chi, PhD

 
Time Topic Speaker(s)
10:15-11:00 am Decoding the pathogenic non-coding genome in blood cancers Jian Xu, PhD
11:00-11:30 am Panel Discussion: Immunotherapy Initiatives at St. Jude Moderator: Stephen Gottschalk
Panel: Hongbo Chi, Julie ParkPaul Thomas, Stephen Gottschalk
 
11:30 am- 12:45 pm Lunch and poster viewing
 

Session III

Chair: Jaquelyn Zoine, PhD

 
Time Topic Speaker(s)
12:45-1:05 pm Featured: Update on St. Jude Clinical Research Administration Elizabeth Fox, MD, MS (Clinical Trials Administration)
1:05-1:20 pm Chemokine receptor mediated homing of CAR T cells Lindsay Talbot, MD
1:20-1:35 pm Learning the rules of endogenous antitumor immune responses Ricky Tirtakusuma, PhD  (Thomas Lab)
1:35-1:50 pm Go with the flow: monitoring clinical trials Deanna Langfitt, PhD (BMTCT Flow Cytometry and Cell Sorting Core)
1:50-2:05 pm B7-H3 CAR T cells for pediatric solid tumors: 3CAR clinical update Rebecca Epperly, MD
2:05-2:20 pm Break
 

Session IV

Chair: Meghan Dukes, PhD

 
Time Topic Speaker(s)
2:20-2:40 pm Featured: Tackling the often-forgotten foe in cancer immunotherapy and the Department of Host-Microbe Interactions Victor Torres, PhD (Host Microbe Interactions)
2:40-2:55 pm (CETi2) Taking immunoinformatics into the future Jeremy Chase Crawford, PhD, Immunology, CeTI2 (footnote: Center for Translational Immunology and Immunotherapy)
2:55-3:10 pm DAMP-mediated T cell dysfunction in AML Grace Ward, PhD (Youngblood and Zebley labs)​
3:10-3:25 pm Clinical update: CAR T cell therapy for AML Swati Naik, MBBS
3:25-3:40 pm Break
 

Session V

Chair: Sarah Moore

 
Time Topic Speaker(s)
3:40-3:55 pm Alternative signaling underlies CD7 negative T cell biology and CAR effector function Chris Nevitt, PhD (Velasquez Lab)
3:55-4:10  pm The Pore forming protein Gasdermin E antagonizes tumor cell recovery from apoptosis and consequent mutagenesis Beiyun Liu, PhD (Green Lab)
4:10-4:25 pm BMTCT’s Immune Monitoring Core: What do we do? Jean-Yves Metais, PhD (Immune Monitoring Core-Molecular)
4:25-4:40 pm Clinical Update Aimee Talleur, MD
4:40-4:50 pm Wrap-up Paulina Velasquez, MD; Giedre Krenciute, PhD; Paul Thomas, PhD
4:50-6:00 pm Poster viewing and Happy Hour
6:00-8:00 pm Dinner
 
 
Close